MIVAC Development develops a new promising vaccine against gastric ulcer and gastric cancer.
New board members strengthen MIVAC Development’s expertise in commercial pharmaceutical operations and include a voice for the scientists at the MIVAC research center.
MIVAC Development held General Assembly & Celebrated our new localities.
A letter of intent was filed with BioInvent regarding the AD-project.
The Swedish Patent and Registration Office approved the MIVAC trademark.
PCT-application was filed for the AD-project to the Swedish Patent and Registration Office.
Swedish Foundation for Strategic Research (SSF) granted the research center MIVAC an additional 6 MSEK.
Vinnova funded the verification process in the Tolerance project over a two year period.
MIVAC Development AB Annual report.
MIVAC Development’s Annual report was presented.